Mia Maamari
A5052756461- Kawasaki Disease and Coronary Complications
- COVID-19 Clinical Research Studies
- COVID-19 Impact on Reproduction
- SARS-CoV-2 and COVID-19 Research
- Vaccine Coverage and Hesitancy
- Respiratory viral infections research
- Mechanical Circulatory Support Devices
- Long-Term Effects of COVID-19
- Respiratory Support and Mechanisms
- Pneumonia and Respiratory Infections
- Viral gastroenteritis research and epidemiology
- COVID-19 and Mental Health
- Neonatal Respiratory Health Research
- Respiratory and Cough-Related Research
- CAR-T cell therapy research
- Childhood Cancer Survivors' Quality of Life
- Cardiovascular Issues in Pregnancy
- Healthcare Systems and Practices
- Cardiovascular Effects of Exercise
- Global Maternal and Child Health
- Emergency and Acute Care Studies
- Nosocomial Infections in ICU
- Pluripotent Stem Cells Research
- Ethics and Legal Issues in Pediatric Healthcare
- Pregnancy and Medication Impact
The University of Texas Southwestern Medical Center
2019-2024
Children's Medical Center
2021-2024
Children's Healthcare of Atlanta
2023
Texas Children's Hospital
2023
Children's Hospital of Philadelphia
2023
Emory University
2023
Nationwide Children's Hospital
2023
Centers for Disease Control and Prevention
2023
Children's Hospital of New Orleans
2023
Lurie Children's Hospital
2022
<h3>Importance</h3> Refinement of criteria for multisystem inflammatory syndrome in children (MIS-C) may inform efforts to improve health outcomes. <h3>Objective</h3> To compare clinical characteristics and outcomes adolescents with MIS-C vs those severe coronavirus disease 2019 (COVID-19). <h3>Setting, Design, Participants</h3> Case series 1116 patients aged younger than 21 years hospitalized between March 15 October 31, 2020, at 66 US hospitals 31 states. Final date follow-up was January...
Coronavirus disease 2019 (COVID-19) affects the nervous system in adult patients. The spectrum of neurologic involvement children and adolescents is unclear.To understand range severity among associated with COVID-19.Case series patients (age <21 years) hospitalized between March 15, 2020, December positive severe acute respiratory syndrome coronavirus 2 test result (reverse transcriptase-polymerase chain reaction and/or antibody) at 61 US hospitals Overcoming COVID-19 public health...
The assessment of real-world effectiveness immunomodulatory medications for multisystem inflammatory syndrome in children (MIS-C) may guide therapy.
Multisystem inflammatory syndrome in children (MIS-C) is a severe postinfectious hyperinflammatory condition, which generally occurs 2-6 weeks after typically mild or asymptomatic infection with SARS-CoV-2, the virus that causes COVID-19 (1-3). In United States, BNT162b2 (Pfizer-BioNTech) vaccine currently authorized for use and adolescents aged 5-15 years under an Emergency Use Authorization fully licensed by Food Drug Administration persons ≥16 (4). Prelicensure randomized trials ≥5...
Spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) B.1.1.529 (omicron) variant, which led to increased U.S. hospitalizations for disease 2019 (Covid-19), generated concern about immune evasion and duration protection from vaccines in children adolescents.Using a case-control, test-negative design, we assessed vaccine effectiveness against laboratory-confirmed Covid-19 leading hospitalization critical (i.e., receipt life support or death). From July 1, 2021, February...
Infants younger than 6 months of age are at high risk for complications coronavirus disease 2019 (Covid-19) and not eligible vaccination. Transplacental transfer antibodies against severe acute respiratory syndrome 2 (SARS-CoV-2) after maternal Covid-19 vaccination may confer protection in infants.
The increasing incidence of pediatric hospitalizations associated with coronavirus disease 2019 (Covid-19) caused by the B.1.617.2 (delta) variant severe acute respiratory syndrome 2 (SARS-CoV-2) in United States has offered an opportunity to assess real-world effectiveness BNT162b2 messenger RNA vaccine adolescents between 12 and 18 years age.
Previous studies of severe acute respiratory syndrome coronavirus 2 infection in infants have incompletely characterized factors associated with illness or focused on born to mothers disease 2019 (COVID-19). Here we highlight demographics, clinical characteristics and laboratory values that differ between without COVID-19.Active surveillance was performed by the Overcoming COVID-19 network identify children adolescents 2-related hospitalized at 62 sites 31 states from March 15 December 27,...
Pediatric COVID-19 vaccination is effective in preventing COVID-19-related hospitalization, but duration of protection the original monovalent vaccine during SARS-CoV-2 Omicron predominance merits evaluation, particularly given low coverage with updated vaccines.During December 19, 2021-October 29, 2023, Overcoming Network evaluated effectiveness (VE) ≥2 mRNA doses against hospitalization and critical illness among U.S. children adolescents aged 5-18 years, using a case-control design.Too...
Multisystem inflammatory syndrome in children (MIS-C) consensus criteria were designed for maximal sensitivity and therefore capture patients with acute COVID-19 pneumonia.We performed unsupervised clustering on data from 1,526 (684 labeled MIS-C by clinicians) <21 years old hospitalized COVID-19-related illness admitted between 15 March 2020 31 December 2020. We compared prevalence of assigned labels clinical features among clusters, followed recursive feature elimination to identify...
OBJECTIVES: Extracorporeal membrane oxygenation (ECMO) has been used successfully to support adults with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-related cardiac or failure refractory conventional therapies. Comprehensive reports of children and adolescents SARS-CoV-2–related ECMO for conditions, including multisystem inflammatory in (MIS-C) COVID-19, are needed. DESIGN: Case series patients from the Overcoming COVID-19 public health surveillance registry. SETTING:...
Importance In 2020 during the COVID-19 pandemic, neurologic involvement was common in children and adolescents hospitalized United States for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)–related complications. Objective To provide an update on spectrum of SARS-CoV-2–related among 2021. Design, Setting, Participants Case series investigation patients reported to public health surveillance with illness between December 15, 2020, 31, 2021, 55 US hospitals 31 states follow-up at...
Abstract Background Community-onset bacterial coinfection in adults hospitalized with coronavirus disease 2019 (COVID-19) is reportedly uncommon, though empiric antibiotic use has been high. However, data regarding and children critical illness from COVID-19 are scarce. Methods We evaluated adolescents aged &lt;19 years admitted to a pediatric intensive care or high-acuity unit for between March December 2020. Based on qualifying microbiology results the first 3 days of admission, we...
Abstract Background It is unclear how acute coronavirus disease 2019 (COVID-19)-directed therapies are used in children with life-threatening COVID-19 US hospitals. We described characteristics of hospitalized the intensive care unit or step-down (ICU/SDU) who received COVID-19-directed and specific administered. Methods Between March 15, 2020 December 27, 2020, &lt;18 years age ICU/SDU at 48 pediatric hospitals United States were identified. Demographics, laboratory values, clinical...
The treatment of children with multisystem inflammatory syndrome in (MIS-C) related to SARS-CoV-2 infection involves immunomodulatory therapies such as IVIG and steroids. Anakinra, an interleukin-1 receptor inhibitor, has also been used, but its effectiveness is not established yet. As optimal regimens for MIS-C remain unknown, we aimed assess the effect anakinra reducing hospital stay patients MIS-C.We included admitted from May 2020 2021 diagnosed based on CDC criteria. exposure interest...
Background and objectives: In June 2022, the mRNA COVID-19 vaccination was recommended for young children. We examined clinical characteristics factors associated with status among vaccine-eligible children hospitalized acute COVID-19. Methods: enrolled inpatients 8 months to <5 years of age community-acquired across 28 US pediatric hospitals from September 20, 2022 May 31, 2023. assessed demographic factors, including highest level respiratory support, defined as unvaccinated,...
In infants hospitalized for bronchiolitis on non-invasive ventilation (NIV) via the RAM cannula nasal interface, variables predicting subsequent intubation, or NIV non-response, are understudied. We sought to identify predictors of non-response.We performed a retrospective cohort study in admitted respiratory failure from placed quaternary children's hospital. excluded children with concurrent sepsis, critical congenital heart disease, preexisting tracheostomy. The primary outcome was...
OBJECTIVES: To describe the rate of high-flow nasal cannula (HFNC) nonresponse and paired physiometric responses (changes [∆] in heart [HR] respiratory [RR]) before after HFNC initiation hospitalized children with bronchiolitis. METHODS: We performed a single-center, prospective descriptive study PICU within quaternary referral center, assessing aged ≤2 years admitted for bronchiolitis on from November 2017 to March 2020. excluded cystic fibrosis, airway anomalies, pulmonary hypertension,...
(Abstracted from N Engl J Med 2022;387:109–119) COVID-19 during pregnancy is associated with a greater risk of adverse outcomes and neonatal complications. Studies have shown that mRNA vaccines are highly effective in preventing severe pregnancy, the Centers for Disease Control Prevention recommends vaccination, including boosters, people who pregnant or plan to be pregnant.
Abstract Background We aimed to determine if pre-existing immunocompromising conditions (ICCs) were associated with the presentation or outcome of patients acute coronavirus disease 2019 (COVID-19) admitted for pediatric intensive care. Methods Fifty-five hospitals in 30 US states reported cases through Overcoming COVID-19 public health surveillance registry. Patients &lt;21 years 12 March 2020–30 December 2021 care unit (PICU) high-acuity included. Results Of 1274 patients, 105 (8.2%)...
Poor documentation and understanding of the limitations life-sustaining therapies upon admission to pediatric intensive care unit (PICU) can result in moral distress for both providers families. Limitations treatments are often not documented and/or understood by members health team.We performed a quality improvement initiative improve teams' paper PICU quaternary children's hospital from January 2018 March 2019. We implemented series plan-do-study-act cycles, including initiation an updated...
Maamari, Mia; Vats, Atul; Fortenberry, James; Hopkins, Clara; Spafford, Patrick; Walson, Karen; Kamat, Pradip
Abstract Background The treatment of children with multisystem inflammatory syndrome in (MIS-C) related to SARS-CoV-2 infection involves immunomodulatory therapies such as IVIG and steroids. Anakinra, an interleukin-1 receptor inhibitor, has also been used, but its effectiveness is not established yet. As optimal regimens for MIS-C remain unknown, we aimed assess the effect anakinra reducing hospital stay patients MIS-C. Methods We included admitted from May 2020 2021 diagnosed based on CDC...